Axsome Therapeutics (AXSM) Interest & Investment Income (2015 - 2026)

Axsome Therapeutics has reported Interest & Investment Income for 12 years, with the latest figure at -$1.2 million in Q1 2026.

• Quarterly Interest & Investment Income rose 51.25% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.3 million (up 32.92% YoY) and the FY2025 annual result came in at -$6.6 million, changed 0.18% from the prior year.
• Interest & Investment Income retreated to -$1.2 million in Q1 2026 per AXSM's latest filing, from -$1.2 million in the prior quarter.
• Over five years, Interest & Investment Income peaked at -$702000.0 in Q4 2023 and troughed at -$2.7 million in Q2 2023.
• A 5-year average of -$1.7 million and a median of -$1.3 million in 2022 frame the typical range for Interest & Investment Income.
• The sharpest annual moves came in 2023 and 2024: Interest & Investment Income jumped 68.6% in 2023, then tumbled 214.81% in 2024.
• Over 5 years, Interest & Investment Income stood at -$1.3 million in 2022, then jumped by 46.94% to -$702000.0 in 2023, then sank by 214.81% to -$2.2 million in 2024, then soared by 46.97% to -$1.2 million in 2025, then slipped by 1.11% to -$1.2 million in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered -$1.2 million, -$1.2 million, and -$1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.